British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

The film and photos are part of a national public health initiative, THRIVE@50+, that GSK is running to educate people 50 and older about their risk for shingles. GSK is encouraging people to ask ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares opened today at p1,644. ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...